Research Article Details

Article ID: A11696
PMID: 30788556
Source: Abdom Radiol (NY)
Title: Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
Abstract: PURPOSE: To investigate the performance of MR-based texture analysis (TA) for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). METHODS: Fifty-four adult patients (33 females, 21 males, mean age 49.8&#8201;&#177;&#8201;13.5&#160;years) with biopsy-proven NAFLD were enrolled and underwent MR imaging on a 1.5&#8201;T system. TA parameters were extracted on axial noncontrast 3D-GRE T1W images (slice thickness&#8201;=&#8201;4.6&#160;mm) using a commercially available research software (TexRAD). Receiver operating curves (ROC), areas under the ROC (AUROC) and 95% confidence intervals (CI) were calculated to assess the accuracy of each TA parameter for the diagnosis of significant (F&#8201;&#8805;&#8201;2) and advanced fibrosis (F&#8201;&#8805;&#8201;3). The correlation between TA and histopathological features of nonalcoholic steatohepatitis (NASH) was tested calculating the Spearman's rank correlation coefficient (&#961;). RESULTS: Thirty-seven (68%) subjects had significant fibrosis and 20 (37%) had advanced fibrosis. The TA parameters with the best performance were standard deviation (SD) and entropy, respectively, with AUROC 0.755 (95% CI 0.619-0.862, p&#8201;&#8804;&#8201;0.0002) and 0.769 (95% CI 0.634-0.873, p&#8201;<&#8201;0.0001) for significant fibrosis and AUROC 0.746 (95% CI 0.609-0.854, p&#8201;&#8804;&#8201;0.0004) and 0.754 (95% CI 0.618-0.861, p&#8201;&#8804;&#8201;0.0002) for advanced fibrosis. SD and entropy demonstrated a moderate correlation with the degree of fibrosis (&#961;&#8201;=&#8201;0.457 and 0.480; p&#8201;<&#8201;0.01). No significant correlation was found between TA parameters and other histopathological features of NASH. CONCLUSIONS: Entropy and SD extracted on T1-weighted MR images have fair accuracy for the diagnosis of significant and advanced hepatic fibrosis in patients with NAFLD.
DOI: 10.1007/s00261-019-01931-6